Description
Anti-amyloid antibodies (lecanemab, donanemab) have ~0.1% brain penetrance. Engineering improved BBB transcytosis via transferrin receptor, LRP1, or novel shuttle peptides could dramatically improve efficacy.
Resolution criteria
Resolved when: comparative evidence shows which BBB transport strategy improves antibody brain exposure beyond baseline lecanemab/donanemab penetrance while preserving target engagement and safety. Required deliverables are a cited dataset or review of transferrin receptor, LRP1, shuttle peptide, and related platforms, KG edges connecting transporters, antibody constructs, brain regions, and outcomes, and a scored hypothesis defining the minimum exposure/efficacy threshold.
Evidence summary
{“hypothesis_matches”: [{“id”: “h-4dd0d19b”, “title”: “LRP1-Dependent Tau Uptake Disruption”, “target_gene”: “LRP1”, “target_pathway”: “LRP1 receptor-mediated transcytosis”, “match_score”: 0.7, “composite_score”: 0.4447540669013228, “status”: “proposed”}, {“id”: “h-959a4677”, “title”: “Blood-Brain Barrier SPM Shuttle System”, “target_gene”: “TFRC”, “target_pathway”: “Transferrin receptor / BBB transcytosis”, “match_score”: 0.5, “composite_score”: 0.5351197777903628, “status”: “proposed”}, {“id”: “h-b948c32c”, “title”: “Engineered Apolipoprotein E4-Neutralizing Shuttle Peptides”, “target_gene”: “APOE, LRP1, LDLR”, “target_pathway”: “Apolipoprotein E lipid transport”, “match_score”: 0.44, “composite_score”: 0.4913197211784866, “status”: “proposed”}, {“id”: “h-aa2d317c”, “title”: “Magnetosonic-Triggered Transferrin Receptor Clustering”, “target_gene”: “TFR1”, “target_pathway”: “Blood-brain barrier transport”, “match_score”: 0.44, “composite_score”: 0.4206402486635706, “status”: “proposed”}, {“id”: “h-84808267”, “title”: “Synthetic Biology BBB Endothelial Cell Reprogramming”, “target_gene”: “TFR1, LRP1, CAV1, ABCB1”, “target_pathway”: “LRP1 receptor-mediated transcytosis”, “match_score”: 0.4, “composite_score”: 0.522661166107546, “status”: “proposed”}, {“id”: “h-7e0b5ade”, “title”: “Circadian-Synchronized LRP1 Pathway Activation”, “target_gene”: “LRP1, MTNR1A, MTNR1B”, “target_pathway”: “LRP1 receptor-mediated transcytosis”, “match_score”: 0.4, “composite_score”: 0.48267825282356064, “status”: “proposed”}, {“id”: “h-23a3cc07”, “title”: “Dual-Domain Antibodies with Engineered Fc-FcRn Affinity Modulation”, “target_gene”: “FCGRT”, “target_pathway”: “Neonatal Fc receptor / antibody transcytosis”, “match_score”: 0.37, “composite_score”: 0.5580009023650041, “status”: “proposed”}, {“id”: “h-73e4340b”, “title”: “Pericyte Contractility Reset via Selective PDGFR-\u03b2 Agonism”, “target_gene”: “PDGFRB”, “target_pathway”: “Blood-brain barrier transport”, “match_score”: 0.3, “composite_score”: 0.41877335787359243, “status”: “proposed”}, {“id”: “h-7dfdc5d7”, “title”: “Mitochondrial-Cytokine Axis Modulation”, “target_gene”: “Mitochondrial respiratory complexes and inflammatory cytokine receptors”, “target_pathway”: null, “match_score”: 0.2, “composite_score”: 0.4413417349914164, “status”: “proposed”}, {“id”: “h-8b7727c1”, “title”: “Targeting Bacterial Curli Fibrils to Prevent \u03b1-Synuclein Cross-Seeding”, “target_gene”: “CSGA”, “target_pathway”: “Bacterial curli amyloid \u2192 \u03b1-synuclein cross-seeding (gut-brain axis)”, “match_score”: 0.2, “composite_score”: 0.4361439227893742, “status”: “proposed”}], “total_matching_hypotheses”: 10, “gap_tokens_sample”: [“BBB”, “LRP1”, “amyloid”, “anti-amyloid”, “antibodies”, “antibody”, “barrier”, “blood”, “blood-brain”, “brain”, “donanemab”, “dramatically”, “efficacy”, “engineering”, “improve”], “updated_at”: “2026-04-06T08:21:05.723055+00:00”}